Induction of hapten-specific tolerance of human CD8+ urushiol (poison ivy)-reactive T lymphocytes

Journal of Investigative Dermatology

Volumn 108, Issue 3, 1997, Pages 253-257

  Kalish, Richard S ^a   Wood, Jonathan A ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b NONE

Author keywords

anergy; antigen presentation; co stimulatory molecules

Indexed keywords

B7 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0031050916     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12286447     Document Type: Article

References (37)

1. Baer H: Chemistry and immunology of poisonous Anacardiaceae. Clin Dermatol 4:152-159, 1986
2. Byck JS, Dawson CR: Assay of protein-quinone coupling involving compounds structurally related to the active principle of poison ivy. Anal Biochem 25:123-135, 1968
3. Damle NK, Mohagheghpour N, Hansen JA, Engelman EG: Alloantigen-specific cytotoxic and suppressor T lymphocytes are derived from phenotypically distinct precursors. J Immunol 131:2296-300, 1983
4. Dawson CR: The chemistry of poison ivy. Trans NY Acad Sci 18:427-443, 1956
5. Fernandez-Ruiz E, Somoza C, Sanchez-Madrid F, Lanier LL: CD28/CTLA-4 ligands: the gene encoding CD86 (B70/B7.2) maps to the same region as CD80 (B7/B7.1) gene in human chromosome 3q13-q23. Eur J Immunol 25:1453-1456, 1995
6. Fields PE, Gajewski TF, Fitch FW: Blocked ras activation in anergic CD4+ T cells. Science 271:1276-1278, 1996
7. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB, Gray GS, Nadler LM, Sharpe AH: Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907-909, 1993b
8. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, Gray GS, Gribben JG, Nadler LM: B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523-532, 1995
9. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, Gray GS, Nadler LM: Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909-911, 1993a
10. Gaspari AA, Ferbel B, Chen Z, Razvi F, Polakowska R: Accessory and alloantigen-presenting cell functions of A431 keratinocytes that stably express the B7 antigen. Cell Immunol 149:291-2, 1993
11. Gimm CD, Freeman GJ, Gribben JG, Sugita K, Freeman AS, Morimoto C, Nadler LM: B-cell surface antigen B7 provides a costimulatory signal that induced T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 88:6575-6579, 1991
12. Griffiths CEM, Voorhees JJ, NickolofF BJ: Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 20:617-629, 1989
13. Gross JA, Callas E, Allison JP: Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 149:380-388, 1992
14. Guo Y, Wu Y, Zhao M, Kong XP, Liu Y: Mutational analysis and an alternatively spliced product ot B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain. J Exp Med 181:1345-1355, 1995
15. Harding FA, McArthur JG, Groos JA, Raulet DH, Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607-609, 1992
16. Hathcock KS, Laszio G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ: Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262:905-907, 1993
17. Jenkins MK, Taylor PS, Norton SD, Urdahl KB: CD28 delivers a costimulatory signal involved in antigen-specific IL2 production by human T cells. J Immunol 147:2461-2466, 1991
18. Kalish RS, Johnson KL: Enrichment and function of urushiol (poison ivy) specific T-lymphocytes in lesions of allergic contact dermatitis tn urushiol. J Immunol 145:3706-3713, 1990
19. Kalish RS, Morimoto C: Qualification and cloning of human urushiol specific peripheral blood T-cells: Isolation of urushiol specific suppressor T-cells. J Invest Dermatol 92:46-52, 1989
20. Kalish RS, Morimoto C: Urushiol (poison ivy) triggered suppressor T-cell clone generated from peripheral blood. J Clin Invest 82:825-832, 1988
21. Kalish RS, Morimoto C, Schlossman SF: Characterization ot the T4 helper inducer subset for the generation of cytotoxicity to alloantigen. Cell Immunol 111:379-389, 1988
22. Kalish RS, Wood JA, LaPorte A: Processing of urushiol (poison ivy) hapten by both endogenous and exogenous pathways for presentation to human T-cells. J Clin Invest 93:2039-2047, 1994
23. Lenshow DH, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257:789-792, 1992
24. Li W, Whaley CD, Mondino A, Mueller DL Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science 271:1272-1276, 1996
25. Linsley PS, Brady W, Urnes M, Grosmaire L, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561-569, 1991
26. Linsley PS, Greene JL, Brady W, Bajorath J, Ledhetter JA, Peach R: Human B7-1 (CD80) and B7-2 (CD86) hind with similar avidities hut distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793-801, 1994
27. Nasir A, Ferbel B, Salminen W, Barth RK, Gaspari AA: Exaggerated and persistent cutaneous delayed-type hypersensitivity in transgenic mice whose epidermal keratinocytes constitutively express B7-1 antigen. J Clin Invest 94:892-8, 1994
28. Quill H, Schwartz RH: Stimulation of normal inducer T cell clones with antigen presented by purified 1a molecules in planar lipid membranes: specific induction of a long-lived state of proliterative nonresponsiveness. J Immunol 138:3704-3712, 1987
29. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065-1068, 1992
30. Simon JC, Dietrich A, Mielke V, Wuttig C, Vanscheidt W, Linsley PS, Schopf E, Sterry W: Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell mediated skin diseases. J Invest Dermatol 103:539-43, 1994
31. Strange P, Skov L, Baadsgaard O: Interferon gamma-treated keratinocytes activate T cells in the presence of superantigens: Involvement of major histocompatibility complex class II molecules. J Invest Dermatol 102:150-154, 1994
32. Symington FW, Brady W, Linsley PS: Expression and function of B7 by human epidermal Langerhans cells. J Immunol 150:1286-1295, 1993
33. Tan R, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, Linsley PS: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 177:165-173, 1993
34. Tan R, Teh SJ, Ledbetter JA, Linsley PS, Teh HS: B7 costimulates proliferation of CD4-8+ T lymphocytes but is not required for the deletion of immature CD4+8+ thymocytes. J Immunol 149:3217-24, 1992
35. Waterhouse P, Penniger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988, 1995
36. Williams IR, Ort RJ, Kupper TS: Keratinocyte expression of B7-1 in transgenic mice amplifies the primary immune response to cutaneous antigens. Proc Natl Acad Sci USA 91:12780-12784, 1994
37. Young JW, Koulova L, Soergel SA, Clark EA, Steinman RM, Dupont B: The B7/BB1 antigen provides one of the several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest 90:229-237, 1992